ASRS 2019 Street Team: David S. Boyer, MD

David S. Boyer, MD, notes that the goal is to dry every patient out, with undertreatment the leading cause of a loss of visual acuity.

David S. Boyer, MD, shares the take-home message from the presentation he delivered at the 2019 meeting of the American Society of Retina Specialists, "The Average Patient Does Not Enter Your Office: What Can We Learn About Treating nAMD From Individual Patient Responses."

Related Videos
How to diagnose geographic atrophy earlier
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
DAVIO trial update: 12-month safety results indicate no serious adverse events, reduced treatment burden
Phase 4 Paladin finds fluocinolone to be safe, effective in patients with diabetic macular edema
Foundation Fighting Blindness: Building a toolbox of therapies for dry AMD, inherited retinal diseases
Faricimab for DME: Personalized treatment interval dosing maintains visual acuity, reduces treatment burden
Diabetic retinopathy eye drop: Phase 1B clinical results show promise
Related Content
© 2023 MJH Life Sciences

All rights reserved.